TradingView
JetEquities
Dec 19, 2019 5:56 PM

Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxi Long

NASDAQ:ATOS30
Atossa Therapeutics, Inc.NASDAQ

Description

⋅
ATOS: Atossa Genetics Inc.
2019-12-19 08:30:10
Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women
Beyond Technical Analysis
More